ABBV - AbbVie Inc
A biopharmaceutical leader best known for Humira — the world's best-selling drug — now pivoting its pipeline toward immunology, oncology, and neuroscience.
Finlify Score
42.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$257.41
-2.24%
52W Range
$187.62 - $261.63
Market Cap
$444.6B
-2.2%Compared to previous day
2026 Q1 Revenue
$15.0B
-9.7%Changes from last reporting quarter
2026 Q1 EPS
$0.39
Diluted shares
Analyst Rating
39 analysts in latest ratings feed
RSI
61.2
40-70 moderate
2Y Range Position
90%
-3.8% from high / +57.1% from low
Beta
0.27
Relative to market benchmark
MACD
-0.31
MACD line 6.28 / signal line 6.59
Fundamental Trend
Growth 9.2Financial Health
Quality 47.6Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID42.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $15.0B-9.7% | $16.6B+5.3% | $15.8B+2.3% | $15.4B+15.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $4.0B-12.2% | $4.5B+138.7% | $1.9B-61.1% | $4.9B+31.1% |
| Net Income | $695M-61.7% | $1.8B+876.3% | $186M-80.2% | $938M-27.1% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
The Finlify signal for ABBV as of 2026-07-23 is HOLD, with an overall Finlify Score of 49.2 out of 100. This stance appears to be influenced by strong technical momentum alongside weaker fundamental trends.
Technical
The asset exhibits robust technical strength, indicated by a Relative Strength score of 59.4/100 and a very high Accumulation / Volume score of 97.8/100, suggesting significant buying interest. Recent performance includes a 20-day return of 9.4% and a 60-day return of 30.2%, with the asset trading close to its 52-week high at -1.6%. The RSI of 64.1 also suggests positive momentum.
Fundamentals
Fundamentally, the asset shows a low Fundamental Trend score of 9.2/100, which may indicate some underlying challenges, despite a moderate Financial Quality score of 47.6/100. Valuation metrics appear elevated, with a P/E ratio of 107.4x, P/B of 94.4x, and P/S of 7.4x. The asset's Beta of 0.3 suggests lower volatility relative to the broader market, and it offers a Dividend Yield of 2.69%.
Macro Context
In a macro environment with a 10Y Treasury Yield at 4.7% and a 2Y Treasury Yield at 4.3%, the positive yield spread of 0.4% may suggest a less inverted yield curve, potentially influencing investor sentiment. Inflation metrics like CPI YoY at 3.7% and Core PCE YoY at 3.4% could impact future discount rates and the cost of capital, potentially affecting growth-oriented assets.
Key Risks
- Elevated valuation metrics, including a P/E ratio of 107.4x, may suggest the asset is priced for significant future growth.
- A low Fundamental Trend score of 9.2/100 could indicate underlying fundamental challenges or decelerating business performance.
- Upcoming earnings on 2026-07-31 present an event risk, where results could significantly impact the stock price.